Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (4584)	12/15/2015 10:27:46 AM
From: The Ox	Respond to of 8239

Intercept Pharmaceuticals Inc. ( NASDAQ:ICPT) stock surged more than 14% during early trading hours today. The stock surged after Daily Mail reported that the pharmaceutical company has received numerous acquisition offers. To cater to these offers, it has hired JPMorgan. Previously, a rumor surfaced that Shire PLC (NASDAQ:SHPG)—which is still pursing the Baxalta Inc. (NYSE:BXLT) acquisition—is among the top bidders for Intercept. However, Intercept recently received Food and Drug Administration (FDA) approval for obeticholic acid (OCA), a product for chronic liver diseases. The company also announced the initiation of the Combination of OCA and statins for monitoring of Lipids Phase 2 clinical trials. This would include 80 non-alcoholic steatohepatitis patients.